List of Excipients in Branded Drug DEPEN

DEPEN Excipient Strategy and Commercial Opportunities for Penicillamine Tablets

Last updated: August 29, 2026

DEPEN is an immediate-release penicillamine tablet used for Wilson disease, cystinuria and severe active rheumatoid arthritis when conventional treatment is inadequate. Its core drug substance and basic tablet technology are mature, leaving limited opportunity for broad composition-of-matter protection. The strongest commercial opportunities are in reliable supply, low-variability generics, excipient-risk reduction, pediatric administration and differentiated 505(b)(2) products.

The principal formulation constraint is penicillamine's chelating activity. Excipients, manufacturing equipment and packaging should be controlled for trace metals and interactions that could affect potency, dissolution or patient administration. A conventional 125 mg or 250 mg tablet remains the lowest-risk regulatory pathway. Liquid, dispersible, sprinkle or modified-release products may create commercial differentiation but carry greater clinical, stability and bioequivalence risk.

What is DEPEN and which formulation opportunities exist?

DEPEN contains penicillamine, a thiol-containing chelating agent. The product is administered orally and is generally taken on an empty stomach because food and certain co-administered products can reduce or alter absorption. Penicillamine is used in chronic treatment, often requiring long-term adherence and dose adjustments. [1]

Product attribute	DEPEN commercial relevance
Active ingredient	Penicillamine
Strengths	125 mg and 250 mg tablets
Dosage form	Immediate-release oral tablet
Key indications	Wilson disease, cystinuria and severe rheumatoid arthritis
Primary formulation issue	Chelation, trace-metal control and food-related administration requirements
Main competitors	Cuprimine and generic penicillamine products
Highest-probability opportunity	Tablet generic with robust supply and reproducible dissolution
Higher-value opportunity	Pediatric or administration-friendly formulation
Main regulatory route	ANDA for equivalent tablets; 505(b)(2) for materially different dosage forms

DEPEN is not a biologic. Biosimilar competition is therefore irrelevant. Competitive pressure comes from generic penicillamine tablets or capsules, alternative chelators such as trientine, and zinc-based Wilson disease regimens.

What inactive ingredients are used in DEPEN tablets?

Public labeling for penicillamine tablet products identifies conventional tablet excipients, including lactose, microcrystalline cellulose, povidone, crospovidone or other disintegrant systems, silicon dioxide, magnesium stearate and sodium starch glycolate. Exact excipient composition can vary by manufacturer, strength and market authorization. [1,2]

A representative DEPEN-type excipient architecture is:

Functional role	Representative excipients	Formulation purpose
Diluent	Lactose monohydrate, microcrystalline cellulose	Tablet mass and compressibility
Binder	Povidone	Granule and tablet strength
Disintegrant	Sodium starch glycolate, crospovidone	Rapid tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow
Lubricant	Magnesium stearate, stearic acid	Ejection and tooling protection
Film coating	Hypromellose, titanium dioxide and plasticizer systems	Appearance, handling and protection
Processing aid	Purified water or ethanol, where used	Granulation or coating process

The excipient list should be confirmed against the approved label for the specific DEPEN reference product and against the target market's approved generic product. A formulation that merely copies the public inactive-ingredient list does not remove the need to demonstrate pharmaceutical equivalence, bioequivalence, stability and manufacturing consistency.

Which excipients are most important for penicillamine stability?

The highest-priority excipient controls concern metals, oxidation, moisture and processing conditions.

Trace-metal control

Penicillamine binds metals by design. Trace iron, copper, zinc and other metal contaminants can interact with the active ingredient or alter degradation behavior. Suppliers should provide elemental-impurity data, and manufacturing equipment should be assessed for metal shedding and product-contact compatibility.

Elemental impurity control should follow ICH Q3D principles. The relevant risk is not limited to intentionally added mineral excipients. It includes pigments, processing aids, water systems, stainless-steel contact surfaces and poorly controlled raw materials. [3]

Oxidation control

Penicillamine contains a sulfhydryl group and can be vulnerable to oxidation. Excipient selection should minimize peroxide burden and uncontrolled oxidative impurities. Povidone, crospovidone and some polymeric excipients can contain or develop peroxides depending on grade, supplier and storage. Incoming controls may include peroxide value, water content, residual solvents and impurity profiling.

An antioxidant strategy may be technically possible, but it can increase regulatory complexity. The preferred first-line approach is usually control of excipient quality, oxygen exposure, moisture, temperature and packaging rather than adding a new antioxidant with uncertain compatibility.

Moisture management

Moisture can affect tablet hardness, disintegration, chemical stability and coating performance. A low-moisture excipient grade, controlled granulation endpoint and moisture-barrier packaging can be more valuable than a complex formulation change.

High-barrier blister packaging or a tightly closed bottle with a suitable desiccant may support shelf-life extension. Packaging changes should be evaluated with accelerated and long-term stability studies, including assay, related substances, dissolution, water content and tablet mechanical properties.

What excipient strategy is best for a DEPEN generic?

The lowest-risk strategy is a simple, direct-compression or dry-granulated formulation using well-characterized excipients with low elemental impurity and peroxide profiles.

A practical development sequence is:

1. Screen lactose, microcrystalline cellulose and mannitol as diluent systems.
2. Compare crospovidone and sodium starch glycolate for disintegration.
3. Optimize lubricant concentration and blending time because over-lubrication can slow dissolution.
4. Establish controls for iron, copper, zinc, peroxide and moisture.
5. Select packaging early rather than treating it as a late-stage stability variable.
6. Match the reference product's dissolution profile across relevant pH conditions.
7. Demonstrate that inactive ingredients do not create clinically meaningful tolerability or administration differences.

Lactose is commercially attractive because it is inexpensive and widely available. A lactose-free formulation could support a narrow differentiation claim, but the clinical value is likely limited unless the target market contains a documented intolerance or excipient-avoidance segment. Mannitol may offer a cleaner positioning for some patients, but it can increase tablet size, cost or hygroscopicity depending on grade.

A dry-granulation process can reduce water exposure and simplify moisture control. Direct compression can reduce process steps, but it requires favorable powder flow, compressibility and content uniformity. Wet granulation may improve uniformity and tablet robustness but introduces water, drying and potential oxidation variables.

What formulations are protected by DEPEN patents?

No commercially meaningful, enforceable composition-of-matter patent should be expected for penicillamine itself. The active ingredient has been used clinically for decades, and fundamental penicillamine protection is long expired.

Potential protection may instead involve:

• Specific tablet compositions
• Modified-release systems
• Pediatric liquids or dispersible tablets
• Taste-masking systems
• Stability-enhancing excipient combinations
• Packaging and moisture-control systems
• Manufacturing processes
• New therapeutic uses
• Combination products involving zinc, trientine or other Wilson disease therapies

A new formulation patent would need to establish more than routine excipient substitution. A credible claim could require a defined excipient range linked to a measurable technical effect, such as improved stability, dissolution under discriminatory conditions, reduced impurity formation or improved dose uniformity.

The strongest formulation patent strategy would combine composition claims with process and use claims. A weak strategy would claim a conventional lactose-cellulose tablet without unexpected performance data.

When does DEPEN lose exclusivity, and what is the Orange Book status?

DEPEN's fundamental market exclusivity has expired. The relevant commercial question is not loss of originator exclusivity but the status of the current reference-listed product, approved generic products, any listed patents and regulatory availability.

Exclusivity issue	Assessment
Composition-of-matter patent	Expired based on the age of penicillamine
New chemical entity exclusivity	Expired
Orphan exclusivity	Not expected to protect the historical DEPEN product today
Pediatric exclusivity	No current commercial significance identified
Formulation exclusivity	Must be checked against the specific approved product
Orange Book patent barrier	No fundamental patent barrier expected
Generic pathway	ANDA is the likely route for equivalent tablets

FDA's Orange Book identifies approved drug products, reference-listed products, therapeutic equivalence information and certain patent or exclusivity data. [4] Because listings and marketed status can change, the Orange Book entry for the intended reference product should control any launch analysis. A product may remain approved while having limited or interrupted commercial availability, which can affect reference-product sourcing and ANDA strategy.

Are there Paragraph IV challenges to DEPEN?

A Paragraph IV challenge is commercially possible where an applicant seeks approval before expiration of a listed patent. For an old penicillamine tablet, the more likely scenario is an ANDA relying on expired patents or a reference product with no relevant listed patent barrier.

The key Paragraph IV risks are:

• A later-listed formulation patent
• A patent covering a particular dosage form or release profile
• A use patent tied to an approved indication
• A patent covering a combination regimen
• A regulatory exclusivity period attached to a newer product rather than legacy DEPEN

No specific active Paragraph IV litigation or settlement should be assumed without a current PACER, FDA Orange Book and district-court docket review. The historic age of penicillamine reduces the probability of a strong blocking patent, but it does not eliminate product-specific litigation risk.

Which companies compete with DEPEN and penicillamine products?

The competitive field has two levels.

Direct penicillamine competition

Direct competitors include DEPEN, Cuprimine and generic penicillamine products where available. Competition may be limited by manufacturing economics, small patient populations and supply reliability rather than by patent barriers.

Penicillamine products can be commercially difficult because:

• Demand is concentrated in rare diseases.
• Patients may require individualized titration.
• Prescribers may avoid switching stable patients.
• Quality failures can have disproportionate clinical consequences.
• The product has a narrow commercial market compared with common chronic therapies.
• Manufacturing scale may be too small to support multiple suppliers.

Therapeutic competition in Wilson disease

Trientine products, including trientine hydrochloride and trientine tetrahydrochloride products, compete with penicillamine for Wilson disease patients. Zinc salts are also used in selected treatment settings. These products may have stronger current formulation or regulatory differentiation than legacy penicillamine tablets.

Competitive product class	Competitive advantage over penicillamine
Trientine products	Alternative chelation strategy and use in patients who cannot tolerate penicillamine
Zinc therapy	Different mechanism and potentially different tolerability profile
Generic penicillamine	Price and supply competition
Specialty formulations	Potential adherence or pediatric advantages

What commercial opportunities exist for DEPEN excipient reformulation?

1. Reliable tablet generic

This is the most practical opportunity. A supplier that delivers consistent 125 mg and 250 mg tablets, stable supply and clean regulatory documentation can compete even without novel patent protection.

The commercial value comes from dependable availability, low batch failure rates and hospital or specialty-pharmacy acceptance.

2. Pediatric dispersible tablet

Wilson disease can require treatment across pediatric age groups. A dispersible or rapidly disintegrating tablet could reduce swallowing difficulty and support weight-based dosing. The product would need careful control of dose uniformity, taste, dispersion volume and excipient safety.

This opportunity is more likely to require a 505(b)(2) application unless the product can satisfy ANDA requirements against an appropriate reference product.

3. Oral liquid or powder for reconstitution

A liquid could address patients unable to swallow tablets. Penicillamine's chemical stability, taste, microbial control and container compatibility create substantial development requirements. A liquid formulation may also increase dosing errors and storage burdens.

The formulation should avoid excipients that contribute trace metals, reactive impurities or excessive oxidation. Unit-dose packaging could improve dose accuracy but would raise cost.

4. Low-metal excipient platform

A manufacturer could develop a controlled excipient platform with documented elemental impurity and peroxide specifications. This may not produce broad patent protection by itself, but it can reduce development risk and support a defensible quality position.

5. Modified-release formulation

Modified release could reduce dosing frequency, but it is a higher-risk opportunity. Penicillamine's administration relative to food and its dose-titration requirements make pharmacokinetic redesign clinically complicated. The product would need evidence that altered exposure does not impair chelation efficacy or increase toxicity.

6. Combination or co-packaged therapy

A co-packaged penicillamine and zinc regimen could improve treatment organization, but combination use is clinically individualized. A fixed-dose combination would face compatibility, dosing and regulatory hurdles. A co-packaged product may be more feasible than a single-tablet combination but would have limited patent strength unless linked to a validated treatment protocol.

How strong is the patent estate for DEPEN?

The patent estate is weak for the legacy tablet and potentially stronger only for genuinely differentiated products.

Asset type	Patent strength	Commercial assessment
Penicillamine molecule	Very low	Historic protection expired
Conventional immediate-release tablet	Low	Routine formulation features are difficult to protect
Low-metal excipient specification	Low to moderate	Better as a process and quality advantage than a standalone patent
Pediatric dispersible tablet	Moderate	Patentable if linked to unexpected stability, taste or performance data
Oral liquid	Moderate	Possible composition, packaging and stability claims
Modified release	Moderate to high	More defensible technically, but clinically and regulatorily expensive
Combination product	Variable	Dependent on clinical use and dosing architecture
Manufacturing process	Moderate	Stronger if it materially improves impurity control or yield

Patent value should be assessed against actual claims, prosecution history, terminal disclaimers, priority dates, maintenance fees and freedom-to-operate results. A patent application based only on substituting one standard diluent for another is unlikely to create durable market exclusion.

What regulatory status and FDA pathway apply to a new DEPEN product?

An equivalent 125 mg or 250 mg immediate-release tablet would generally be pursued through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to establish pharmaceutical equivalence and bioequivalence to the reference-listed drug, together with current good manufacturing practice compliance and adequate stability data. [5]

A new liquid, dispersible, sprinkle, modified-release or materially different formulation may require a 505(b)(2) application. That route can rely in part on FDA's prior findings for an approved product while requiring new data supporting the changed formulation, dosage form, dosing instructions or clinical performance.

Key regulatory workstreams include:

• Reference-product identification
• Strength-specific pharmaceutical equivalence
• Comparative dissolution
• Bioequivalence strategy
• Excipient safety and maximum daily exposure
• Elemental impurity assessment
• Oxidative impurity control
• Container-closure compatibility
• Stability under long-term and accelerated conditions
• Labeling for empty-stomach administration
• Pediatric-use and administration studies for differentiated products

What generic launch risks exist for DEPEN?

The largest launch risks are operational rather than patent-based.

A generic entrant may face difficulty obtaining a commercially available reference product, maintaining specialized API supply, demonstrating adequate stability, or securing sufficient market volume. A limited number of suppliers can create shortage exposure. Small patient populations can also make price competition destructive without generating meaningful volume.

A launch plan should distinguish among three scenarios:

Launch scenario	Likely outcome
First reliable tablet generic	Potential premium for supply continuity
Multiple conventional generics	Rapid price compression
Differentiated pediatric or liquid product	Smaller volume but potentially higher gross margin
Modified-release product	Higher development cost and uncertain uptake
Supply disruption by incumbent	Temporary opportunity, subject to FDA shortage and sourcing rules

Are there licensing opportunities for DEPEN excipients or formulations?

Licensing opportunities are more likely to involve technology than the legacy DEPEN brand. Potential deal structures include:

• In-licensing a low-moisture or low-metal tablet platform
• Acquiring a pediatric dispersible formulation
• Licensing a taste-masking or oral-liquid system
• Contract manufacturing with dedicated impurity controls
• Regional rights for an ANDA-ready product
• Co-development of a 505(b)(2) formulation
• Supply agreements for pharmaceutical-grade penicillamine API

The most attractive transaction would combine an approved or near-approved product, validated stability data and dependable API supply. An early-stage excipient patent without comparative performance data would have limited standalone value.

Key Takeaways

• DEPEN is an old penicillamine immediate-release tablet with no expected fundamental patent barrier.
• The best near-term opportunity is a reliable 125 mg and 250 mg generic with controlled dissolution and stability.
• Chelation, oxidation, elemental impurities and moisture should drive excipient selection.
• Lactose, microcrystalline cellulose, povidone, disintegrants, silicon dioxide and magnesium stearate are representative conventional excipients.
• Pediatric dispersible tablets and oral liquids offer the clearest formulation differentiation.
• Modified-release and fixed-dose combination products have higher technical and regulatory risk.
• Biosimilar risk does not apply because penicillamine is a small-molecule drug.
• Commercial value is driven more by supply reliability and specialty distribution than by legacy patent exclusivity.
• An ANDA is the likely pathway for an equivalent tablet; a materially different formulation may require 505(b)(2).
• A defensible new patent should claim a demonstrated technical effect, not routine excipient substitution.

FAQs

Can a lactose-free DEPEN generic gain meaningful market share?

Possibly, but lactose avoidance alone is unlikely to create broad differentiation. A lactose-free formulation would need a clear patient or institutional purchasing rationale and competitive pricing.

Is mannitol a suitable replacement for lactose in penicillamine tablets?

Mannitol can be suitable as a diluent, but the formulation must be assessed for compressibility, moisture behavior, tablet size, dissolution and stability. It is not automatically superior to lactose.

Would a penicillamine oral suspension qualify for an ANDA?

Usually not if the reference product is an immediate-release tablet and the suspension introduces a materially different dosage form or administration profile. A 505(b)(2) pathway may be more appropriate.

Can excipient control create a patentable DEPEN product?

Yes, if the claimed excipient combination or process produces a non-obvious, reproducible technical result, such as materially improved stability or impurity control. Routine substitutions generally provide weak protection.

Does penicillamine require a biosimilar development program?

No. Penicillamine is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (n.d.). DEPEN (penicillamine) tablets prescribing information. DailyMed.
2. National Library of Medicine. (n.d.). DailyMed drug label database. https://dailymed.nlm.nih.gov/
3. International Council for Harmonisation. (2014). ICH Q3D: Guideline for elemental impurities.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda
5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process and related guidance. https://www.fda.gov/drugs